LivsMed FY 2025 Annual ReportBeta
LivsMed annual report for FY 2025, filed with DART (Korea Financial Supervisory Service) on March 23, 2026. This page provides AI-powered English analysis including business overview, management discussion & analysis (MD&A), risk factors, and KIFRS consolidated financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE).
LivsMed FY 2025 Annual Report Analysis
Business Overview
- • Minimally invasive laparoscopic surgery instruments sales with ArtiSential 5mm and 8mm shaft products; 2025 sales KRW 49.6B (96.9% of total)
- • Launched ArtiSeal multi-joint vessel sealer with 90° rotation; approved domestically (2023) and US, Japan (2024), EU CE MDR in early 2025; KRW 1.58B sales in 2025
Management Discussion & Analysis
- • Revenue KRW 51,192M (+88.8% YoY from KRW 27,121M); operating loss KRW 22,642M (-14.6% YoY from KRW -26,504M)
- • Domestic market penetration of core product ArtiSential drove revenue growth, supported by increased sales and gross profit
Risk Factors
- • USD 10% exchange rate change impacts pre-tax profit by -KRW 13,769K at year-end 2025, down from ±KRW 49,286K at 2024 year-end
- • Total allowance for doubtful accounts on trade receivables KRW 1,170M at 2025 year-end, nearly doubled from KRW 594M a year ago
LivsMed FY 2025 Key Financial MetricsDART
Total Assets
KRW 201.9B
▲ +279.2% YoY
Operating Cash Flow
-KRW 34.7B
▼ -25.6% YoY
CapEx
KRW 7.2B
▲ +66.5% YoY
Source: KIFRS consolidated financial data from LivsMed annual report on DART. All figures in KRW.
Source: DART (Korea Financial Supervisory Service) · AI summaries generated from the original Korean filing (English output) · Beta: coverage is expanding